| Literature DB >> 26307982 |
Yuan Wang1, Mingwei Wu2, Chunzhi Ai3, Yonghua Wang4.
Abstract
Presently, 151 widely-diverse pyridinylimidazole-based compounds that show inhibitory activities at the TEntities:
Keywords: 3D-QSAR; CoMFA; CoMSIA; DISCOtech; TNF-α; imidazoles; inhibitor; pharmacophore
Mesh:
Substances:
Year: 2015 PMID: 26307982 PMCID: PMC4613192 DOI: 10.3390/ijms160920118
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Self-organizing map showing the distribution of the training and test sets. The test set is labeled in red and the training set in black, respectively. The number equals to the series number of the molecules of the TNF-α release inhibitors.
Figure 2Molecular alignment of all compounds in the data set. (A) Compound 3v was used as a template for alignment, with the common substructure shown in bold, and three important substituents including the R1, R2, and R3 substituents shown in the dashed red border; and (B) Ligand-based alignment model of all the compounds. Molecules are colored in white for common C, blue for N, red for O, yellow for S, cyan for H, and green for F, respectively.
Summary of CoMFA and CoMSIA results.
| PLS Statistics | Model A | Model B | ||
|---|---|---|---|---|
| CoMFA | CoMSIA | CoMFA | CoMSIA | |
| 0.524 | 0.593 | 0.557 | 0.598 | |
| 0.856 | 0.778 | 0.740 | 0.767 | |
| 0.323 | 0.399 | 0.432 | 0.409 | |
| 133.655 | 99.117 | 80.388 | 93.091 | |
| 0.730 | 0.876 | 0.748 | 0.860 | |
| 0.588 | 0.541 | 0.564 | 0.538 | |
| 5 | 4 | 4 | 4 | |
| 0.574 | 0.121 | 0.492 | 0.135 | |
| 0.426 | 0.294 | 0.373 | 0.279 | |
| - | 0.195 | - | 0.158 | |
| - | 0.208 | - | 0.195 | |
| - | 0.181 | - | 0.146 | |
| - | - | 0.135 | 0.086 | |
Q2, cross-validated correlation coefficient; R2ncv, non-cross-validated correlation coefficient; SEE, standard error of estimate; F, F-test value; R2pre, predicted correlation coefficient; SEP, smallest predicted error; OPN, optimum number of components; S, steric hindrance; E, electric charge; H, hydrogen bond; D, hydrogen-bond donor; A, hydrogen bond acceptor; ClogP, calculated logarithm.
Figure 3The correlation plots of the predicted pIC50 values versus the observed pIC50 values using the training set and the test set based on (A) CoMFA model and (B) CoMSIA model. The solid lines are the regression lines for the fitted and predicted bioactivities of training and test compounds, respectively. (more detail in Table S1).
Figure 4CoMFA StDev*Coeff contour plots. (A) Steric (green/yellow) contour map in combination with compound 3v in ball and stick. Green contours indicate regions where bulky groups increase the activity; yellow contours indicate regions where bulky groups decrease the activity; and (B) Electrostatic contour map (red/blue) in combination with compound 3v. Red contours indicate regions where negative charges increase the activity; blue contours indicate regions where positive charges increase the activity.
Figure 5CoMSIA StDev*Coeff (A) steric; (B) electrostatic; (C) hydrophobic; (D) H-bond donor and (E) H-bond acceptor contour maps. The color code is as follows: (A) green and yellow contours indicate favorable and unfavorable bulky groups, respectively; (B) blue and red contours indicate favorable and unfavorable electropositive groups, respectively; (C) yellow and white contours indicate favorable and unfavorable hydrophobic groups, respectively; (D) cyan and purple contours indicate favorable and unfavorable H-bond donor groups, respectively; (E) magenta and red contours indicate favorable and unfavorable H-bond acceptor groups, respectively. The compound 3v in ball and stick is displayed as a reference.
Number of models obtained along with the pharmacophoric features and tolerance values for each of the DISCO pharmacophoric.
| Model | Size a | Hits b | Score c | Tolerance d | Dmean e |
|---|---|---|---|---|---|
| MODEL_006 | 10 | 100 | 4.1075 | 0.25 | 4.5615 |
| MODEL_003 | 10 | 100 | 4.1015 | 0.50 | 4.5264 |
| MODEL_008 | 10 | 100 | 4.1015 | 0.50 | 4.5263 |
| MODEL_007 | 10 | 100 | 3.4537 | 0.50 | 3.7971 |
| MODEL_005 | 10 | 100 | 3.4526 | 0.25 | 3.7925 |
| MODEL_001 | 10 | 100 | 3.4517 | 0.25 | 3.789 |
| MODEL_004 | 10 | 100 | 3.4517 | 0.25 | 3.789 |
| MODEL_002 | 10 | 100 | 3.4516 | 0.25 | 3.7885 |
a, SIZE, number of features in the model; b, HITS, number of molecules that matched during the research; c, SCORE, an overall measure of fit and of overlap for the entire collection of structure; d, TOLERANCE, initial tolerance setting (from 0.25 to 2.5); e, DMEAN, average inter-point distance.
Figure 6Pharmacophore model of DISCOtech. (A) Model_006 with ten features generated presented in template molecule 3v (B) Alignment of 100 molecules. AR represents aromatic center; HP refers to hydrophobic center; DA and AA are short for H-bond donor and acceptor atom, respectively; DS and AS refer to H-bond donor site and H-bond acceptor site, respectively. Molecules are colored in yellow and white for common C, blue for N, red for O, cyan for H, and green for F, respectively.
Figure 7Pharmacophoric features and their distance relation generated by DISCOtech module, AR represents aromatic center; HP refers to hydrophobic center; DA and AA are short for H-bond donor and acceptor atom, respectively; DS and AS refer to H-bond donor site and H-bond acceptor site, respectively.
Relative intramolecular distances between pharmacophoric feature points for model_006 (Å).
| Domain | DS1 | DA1/AA1 | HP1/AR1 | HP2/AR2 | AA2/DA2 |
|---|---|---|---|---|---|
| DA1/AA1 | 3.00 ± 0.25 | – | – | – | – |
| HP1/AR1 | 4.12 ± 0.25 | 1.12 ± 0.25 | – | – | – |
| HP2/AR2 | 7.87 ± 0.25 | 5.05 ± 0.25 | 4.05 ± 0.25 | – | – |
| AA2/DA2 | 9.20 ± 0.25 | 6.41 ± 0.25 | 5.41 ± 0.25 | 1.37 ± 0.25 | – |
| DS2 | 12.16 ± 0.25 | 9.41 ± 0.25 | 8.41 ± 0.25 | 4.37 ± 0.25 | 3.00 ± 0.25 |
AR represents aromatic center; HP refers to hydrophobic center; DA and AA are short for H-bond donor and acceptor atom, respectively; DS and AS refer to H-bond donor site and H-bond acceptor site, respectively.
Figure 8The interaction features of compound 3v impacting the antagonistic activity obtained from our present work.